Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Adv Enzyme Regul. Author manuscript; available in PMC 2012 January 1.
Published in final edited form as:
PMCID: PMC3078998

The role of inositol polyphosphate 4-phosphatase 1 in platelet function using a weeble mouse model


Platelet activation plays an important role in the development and course of cardiovascular disease. It is triggered by the interaction of subendothelial matrix-bound and/or soluble agonists with platelet surface receptors causing a series of morphological and biochemical changes leading to the recruitment of additional platelets and formation of stable platelet aggregates. In addition to events causing initial activation and recruitment of platelets, signaling continues post-aggregation that promotes stability of the thrombus (Brass et al., 2004). Platelet levels of phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) increase dramatically in response to agonist stimulation in an aggregation-dependent manner (Kucera et al., 1990; Nolan et al., 1990; Sultan et al., 1990). Furthermore the increase in platelet PtdIns(3,4)P2 occurs late in platelet aggregation and correlates with the irreversible phase of platelet aggregation (Sorisky et al., 1992; Sultan et al., 1991; Trumel et al., 1999), suggesting that PtdIns(3,4)P2 mediates the stabilization of platelet aggregates. However little is known about the regulation of PtdIns(3,4)P2 in platelets. PtdIns(3,4)P2 can be formed by three different routes 1) by direct phosphorylation of PtdIns(4)P by phosphatidylinositol 3-kinase (EC2.7.1.153) (PI 3-K) 2) by PI 3-K using PtdIns(4,5)P2 as a substrate followed by dephosphorylation by a 5-phosphatase (EC3.1.3.56) and, 3) by the action of type I PtdIns(4)P phosphate kinase (EC2.7.1.68) using PI 3-K as substrate (Zhang et al., 1998), shown diagramatically in figure 1. It is well documented that different PI 3-K isoforms play important roles in both early and later stages of platelet aggregation (Jackson et al., 2006). It has been shown that that pharmacologic inhibition of PI 3-K prevents agonist-induced formation of PtdIns(3,4)P2 (Kovacsovics et al., 1995; Schoenwaelder et al., 2007). Furthermore addition of PI 3-K inhibitors after the onset of platelet aggregation induces a decline in PtdIns(3,4)P2 and disaggregation of platelets, supporting a role for PtdIns(3,4)P2 in the stabilization of aggregates. However, platelet agonist-dependent activation of PI 3-K mediates an increase in both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 making approaches using pharmacologic inhibition or genetic disruption of PI 3-K unsuitable to distinguish the contributions of the individual 3-phosphorylated phosphoinositides to platelet signaling. The levels of inositol lipids in cells and their distribution in discrete cellular compartments are regulated by the balance of the enzymatic activities of kinases and phosphatases.

Figure 1
Pathways for the formation of PtdIns (3,4)P2.

The major route of PtdIns(3,4)P2 hydrolysis is the removal of the D4 phosphate by the enzymes cloned and characterized in our lab (Norris et al., 1997; Norris et al., 1995), inositol polyphosphate 4-phosphatase type I (EC3.1.3.40) and type II (EC3.1.3.66) that are magnesium-independent phosphatases. Over their entire sequence type I and type II 4-phosphatases are 37% identical (Norris et al., 1997). The active site region is more highly conserved, and contains a consensus sequence found in other magnesium-independent phosphatases (Zhang et al., 1994). The consensus sequence CX5 RT/S, is conserved throughout 4-ptases from C. elegans to humans as shown in figure 2. These enzymes do not catalyze the hydrolysis of lipids other than PtdIns(3,4)P2 and therefore provide unique means for the study of this lipid in platelet activation. We have shown that 4-ptase I forms a complex with PI 3-K in platelets which localizes the complex to sites of PtdIns(3,4)P2 production (Munday et al., 1999).

Figure 2
Alignment of active sites of 4ptases.

We postulate that PtdIns(3,4)P2 is important for platelet function and will study this using a mouse model. We previously showed that an antibody that reacts with 4-phosphatases immunoprecipitates all of the PtdIns(3,4)P2 hydrolyzing activity from human platelets (Munday et al., 1999). An early indication that PtdIns(3,4)P2 was important for platelet function was the work of Norris (Norris et al., 1997). It was shown that calpain caused degradation of recombinant 4-phosphatase I in vitro thereby inactivating it. It was also shown that activation of human platelets with either calcium ionophore or thrombin led to proteolysis of endogenous platelet 4-phosphatase I. If calpeptin, a cell-permeable inhibitor of calpain, was included in these experiments no proteolysis was seen. The levels of PtdIns(3,4)P2 in platelets were lower when calpeptin was included, indicating that 4-phosphatase I was important for controlling the levels of PtdIns(3,4)P2 during platelet activation.

A naturally occurring mutation in type I 4-phosphatase is a single nucleotide deletion which is found in the weeble mouse. These animals suffer from severe neurodegeneration and die within the first weeks of life. Therefore such mutant mice cannot be used to study platelet function. We circumvented this problem by creating chimeric mice by bone marrow transplantation of weeble fetal liver cells into lethally irradiated wild type mice. These mice lack 4-phosphatase in bone marrow derived cells including platelets. The mice are viable, but lack platelet 4-phosphatase I.

Results and discussion

To study the role of 4-phosphatase I in the regulation of PtdIns(3,4)P2 in platelets we have obtained mice heterozygous for the weeble mutation from Arne Nystuen, University of Nebraska. The mutation arose spontaneously in the Jackson laboratory mouse colony on a C57Bl/6J background and was identified as a single nucleotide deletion (Δ744G) that led to a frame shift and premature stop codon (Nystuen et al., 2001) (figure 3). Subsequently it was backcrossed 10 generations onto a Balb/cByJ background. The mice homozygous for the mutation lack 4-phosphatase I mRNA and protein and are therefore a good model for studying the functions of 4-phosphatase I. Homozygous mice die in the first weeks of life due to severe neurodegeneration and therefore cannot be used to study platelet function. Initially we measured platelet counts in 3 day old weeble mice and found that they were normal. Thus the animals do not have a defect in thrombocytopoiesis. We then generated radiation chimeras by transplanting weeble fetal liver cells into lethally irradiated wild type mice using the protocol of Hirbe (Hirbe et al., 2007), shown in figure 4. Platelet counts were obtained 4 weeks after transplantation and were found to be normal with wild type mice having 766,000 and weeble mice 718,000 (p=0.68). Platelet lysates from weeble chimeras contained no detectable 4-phosphatase I.

Figure 3
DNA sequences of mouse wild type 4-ptaseI (A) in the region surrounding the weeble mutation and a single nucleotide deletion in the weeble (B), indicated by an arrow. (C) Sequence from a mouse heterozygous for the weeble mutation. Note that following ...
Figure 4
Generation of radiation chimera mice.

We have initiated studies to test the possibility that weeble chimeric mice have a propensity for thrombosis using a carotid artery injury model (He et al., 2002). In this method a segment of mouse carotid artery is isolated and an ultrasonic flow probe is placed distal to the isolated segment in order to measure blood flow. The isolated artery is irradiated with laser light and Rose bengal is injected into the mouse tail vein. The dye is induced to generate free radicals by the laser light which damage the carotid artery causing it to thrombose. The time to cessation of blood flow is measured indicating complete carotid occlusion. In a preliminary experiment the wild type carotid artery thrombosed after 45 minutes (figure 5a) while that from the weeble chimera thrombosed at 22 minutes (figure 5b), a dramatic difference in this model. In future experiments we will measure parameters of in vitro platelet function including platelet aggregation and secretion responses to platelet agonists such as ADP, collagen, and thrombin. We will also measure bleeding time, clot retraction (Leon et al. 2007), and rates of thrombin generation after activation of platelets in vitro. In additional studies using the carotid artery injury model we will determine whether the increased propensity to thrombosis is abrogated by treatment of mice with aspirin to inhibit thromboxane formation (Roth et al., 1975) or with an ADP P2Y12 receptor antagonist (Daniel et al., 1998; Jin et al., 1998). Downstream targets of PtdIns(3,4)P2 will also be studied including Akt activation (Kroner et al., 2000) and its phosphorylation and Rap1b activation (Woulfe et al., 2002).

Figure 5
Blood flow traces from A-Wild type and B-weeble mice.


We thank Arne Nystuen for his generous gift of the weeble mice. We thank Marina Kisseleva for helpful discussions, and Deborah LaFlamme for technical assistance. This work was supported by NIH grant HL-16634-45 to P.W.M. and the Childrens Discovery Institute MD-II-2010-174 to M.P.W.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


  • Brass LF, Stalker TJ, Zhu L, Lu B, Woulfe DS, Prevost N. Boundary events: contact-dependent and contact-facilitated signaling between platelets. Semin Thromb Hemost. 2004;30:399–410. [PubMed]
  • Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024–2029. [PubMed]
  • He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213–219. [PMC free article] [PubMed]
  • Hirbe AC, Rubin J, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A. 2007;104:14062–14067. [PubMed]
  • Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci. 2006;63:1085–1090. [PubMed]
  • Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95:8070–8074. [PubMed]
  • Kovacsovics TJ, Bachelot C, Toker A, Vlahos CJ, Duckworth B, Cantley LC, Hartwig JH. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem. 1995;270:11358–11366. [PubMed]
  • Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J Biol Chem. 2000;275:27790–27798. [PubMed]
  • Kucera GL, Rittenhouse SE. Human platelets form 3-phosphorylated phosphoinositides in response to alpha-thrombin, U46619, or GTP gamma S. J Biol Chem. 1990;265:5345–5348. [PubMed]
  • Munday AD, Norris FA, Caldwell KK, Brown S, Majerus PW, Mitchell CA. The inositol polyphosphate 4-phosphatase forms a complex with phosphatidylinositol 3-kinase in human platelet cytosol. Proc Natl Acad Sci U S A. 1999;96:3640–3645. [PubMed]
  • Nolan RD, Lapetina EG. Thrombin stimulates the production of a novel polyphosphoinositide in human platelets. J Biol Chem. 1990;265:2441–2445. [PubMed]
  • Norris FA, Atkins RC, Majerus PW. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem. 1997;272:23859–23864. [PubMed]
  • Norris FA, Atkins RC, Majerus PW. Inositol polyphosphate 4-phosphatase is inactivated by calpain-mediated proteolysis in stimulated human platelets. J Biol Chem. 1997;272:10987–10989. [PubMed]
  • Norris FA, Auethavekiat V, Majerus PW. The isolation and characterization of cDNA encoding human and rat brain inositol polyphosphate 4-phosphatase. J Biol Chem. 1995;270:16128–16133. [PubMed]
  • Nystuen A, Legare ME, Shultz LD, Frankel WN. A null mutation in inositol polyphosphate 4-phosphatase type I causes selective neuronal loss in weeble mutant mice. Neuron. 2001;32:203–212. [PubMed]
  • Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076. [PubMed]
  • Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem. 2007;282:28648–28658. [PubMed]
  • Sorisky A, King WG, Rittenhouse SE. Accumulation of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in thrombin-stimulated platelets. Different sensitivities to Ca2+ or functional integrin. Biochem J. 1992;286(Pt 2):581–584. [PubMed]
  • Sultan C, Breton M, Mauco G, Grondin P, Plantavid M, Chap H. The novel inositol lipid phosphatidylinositol 3,4-bisphosphate is produced by human blood platelets upon thrombin stimulation. Biochem J. 1990;269:831–834. [PubMed]
  • Sultan C, Plantavid M, Bachelot C, Grondin P, Breton M, Mauco G, Levy-Toledano S, Caen JP, Chap H. Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3',4'-bisphosphate. J Biol Chem. 1991;266:23554–23557. [PubMed]
  • Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94:4156–4165. [PubMed]
  • Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. J Biol Chem. 2002;277:23382–23390. [PubMed]
  • Zhang X, Majerus PW. Phosphatidylinositol signalling reactions. Semin Cell Dev Biol. 1998;9:153–160. [PubMed]
  • Zhang ZY, Wang Y, Wu L, Fauman EB, Stuckey JA, Schubert HL, Saper MA, Dixon JE. The Cys(X)5Arg catalytic motif in phosphoester hydrolysis. Biochemistry. 1994;33:15266–15270. [PubMed]